Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB

NCT02354014 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Tuberculosis, Multidrug-Resistant

Interventions

DRUG: Bedaquiline (TMC207)
DRUG: Background Regimen (BR)

Sponsor

Janssen Research & Development, LLC